| Diabetes Mellitus, Non-Insulin-Dependent
Kombiglyze XR vs Steglatro
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Kombiglyze vs Steglatro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSteglatro has a higher rate of injection site reactions vs Kombiglyze based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Steglatro but not Kombiglyze, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kombiglyze
Steglatro
At A Glance
Oral
Once daily
DPP4 inhibitor + biguanide
Oral
Daily
SGLT2 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Administer once daily with the evening meal; individualize starting dose based on current regimen; max 5 mg saxagliptin/2,000 mg metformin HCl extended-release once daily; limit saxagliptin to 2.5 mg daily with strong CYP3A4/5 inhibitors; swallow tablets whole.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg orally once daily in the morning, with or without food; may increase to 15 mg once daily for additional glycemic control; not recommended when eGFR < 45 mL/min/1.73 m2; withhold at least 4 days prior to surgery or procedures associated with prolonged fasting.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of serious hypersensitivity reaction to saxagliptin, metformin HCl, or any ingredient in KOMBIGLYZE XR, including anaphylaxis, angioedema, or exfoliative skin conditions
- Hypersensitivity to ertugliflozin or any excipient in STEGLATRO (reactions including angioedema have occurred)
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache (saxagliptin); diarrhea, nausea/vomiting (metformin)
Serious Lactic acidosis, pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, vitamin B12 decrease
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, bullous pemphigoid, cholestatic and hepatocellular liver injury
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Serious Diabetic ketoacidosis in type 1 diabetes, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia with insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's Gangrene), genital mycotic infections
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), angioedema, rash
Pharmacology
Kombiglyze XR combines saxagliptin, a competitive DPP4 inhibitor that slows incretin hormone (GLP-1, GIP) inactivation to enhance glucose-dependent insulin release and suppress glucagon, and metformin HCl, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
SGLT2 inhibitor; ertugliflozin inhibits SGLT2, the predominant transporter responsible for renal reabsorption of filtered glucose, thereby lowering the renal threshold for glucose and increasing urinary glucose excretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kombiglyze
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Steglatro
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Kombiglyze
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Steglatro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Kombiglyze
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Steglatro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Kombiglyze.
No savings programs available for Steglatro.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KombiglyzeView full Kombiglyze profile
SteglatroView full Steglatro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.